Testosterone therapy and venous thromboembolism risk in men with and without hypogonadism

JAMA Nov 18, 2019

Walker RF, Zakai NA, MacLehose RF, et al. - In men with and without evidence of hypogonadism, researchers ascertained if short-term testosterone therapy exposure was correlated with increased short-term risk of venous thromboembolism (VTE). They observed an association between the use of testosterone therapy in the 6-month case period and an increased risk of VTE among men with and without hypogonadism in this case-crossover study comparing 6-month testosterone use for 39,622 men who had a VTE with testosterone use 6-12 months before the VTE. Such findings suggest that when prescribing testosterone therapy, caution should be used.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen